Citigroup’s DataMeds AI MEDS Stock Holding History

Citigroup’s Portfolio MEDS Stock Details MEDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.86K	Buy	+1,847	New	+$4.51K	﹤0.01%	5328
2026 Q1	–	Sell	-152	Closed	-$3.03K	–	6511
2025 Q4	$3.03K	Buy	152 +107	+238%	+$3.14K	﹤0.01%	5377
2025 Q3	$2K	Buy	+45	New	+$2.38K	﹤0.01%	5482

Other funds holding MEDS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Citigroup's MEDS Position: Q3 2026 in Review

Citigroup opened a new position in DataMeds AI (MEDS) in Q3 2026: 1,847 shares worth $5.86K. The stake represents ﹤0.01% of the portfolio and ranks #5328 among its holdings. This is a return to the name: Citigroup previously reported a position in MEDS as recently as Q4 2025.

Citigroup first reported a position in MEDS in Q3 2025 and has held it in 3 quarters since. 6 funds tracked by Wall St. Rank hold MEDS as of Q3 2026.

Citigroup held 1,847 shares of DataMeds AI worth $5.86K as of Q3 2026.
DataMeds AI was a new Citigroup position in Q3 2026.
DataMeds AI made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5328 holding.
Citigroup first reported a position in DataMeds AI in Q3 2025 and has held it in 3 quarters since.
6 funds tracked by Wall St. Rank held DataMeds AI as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.